Semaglutide Explored for Smoking Cessation in Diabetes Patients

Type 2 diabetes is a chronic metabolic condition often complicated by nicotine addiction and tobacco dependence, which significantly worsen health outcomes. While semaglutide is a GLP-1 receptor agonist primarily used for blood sugar control and weight management, emerging evidence suggests it might also reduce addictive behaviors. This pilot randomized controlled trial aims to investigate the feasibility and preliminary efficacy of using semaglutide as an adjunct therapy to standard nicotine replacement therapy (NRT) for smoking cessation in this vulnerable patient population.

As this is a "NOT_YET_RECRUITING" pilot study, there are no findings to report yet. However, the researchers aim to assess the feasibility of conducting a larger Phase 3 randomized controlled trial on semaglutide for smoking cessation in Type 2 diabetes patients. They will investigate key metrics such as recruitment rates, participant adherence to the 26-week treatment protocol, and retention rates. The primary objective is to determine if a full-scale trial is viable, while secondary objectives include evaluating preliminary efficacy by comparing smoking cessation rates and reduction in daily cigarette consumption between the semaglutide plus NRT group and the NRT-alone control group. They will also monitor safety and tolerability of semaglutide in this specific population, looking for any adverse events.